TCT-332 FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – First Report on Initial 24 Month Outcomes
Abizaid A, Didier C, Frey N, Lutz M, Weber-Albers J, Dudek D, Chevalier B, Lansky A, Anderson J. TCT-332 FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – First Report on Initial 24 Month Outcomes. Journal Of The American College Of Cardiology 2017, 70: b136. DOI: 10.1016/j.jacc.2017.09.420.Peer-Reviewed Original Research